A detailed history of Hsbc Holdings PLC transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 31,287 shares of DSGN stock, worth $195,543. This represents 0.0% of its overall portfolio holdings.

Number of Shares
31,287
Previous 44,470 29.64%
Holding current value
$195,543
Previous $148,000 13.51%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.19 - $5.88 $42,053 - $77,516
-13,183 Reduced 29.64%
31,287 $168,000
Q2 2024

Aug 12, 2024

SELL
$3.23 - $4.77 $13,950 - $20,601
-4,319 Reduced 8.85%
44,470 $148,000
Q1 2024

May 15, 2024

BUY
$2.27 - $4.03 $8,476 - $15,048
3,734 Added 8.29%
48,789 $196,000
Q4 2023

Feb 12, 2024

BUY
$1.99 - $2.76 $17,044 - $23,639
8,565 Added 23.47%
45,055 $119,000
Q3 2023

Nov 13, 2023

BUY
$2.05 - $8.14 $74,804 - $297,028
36,490 New
36,490 $86,000

Others Institutions Holding DSGN

About Design Therapeutics, Inc.


  • Ticker DSGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,807,900
  • Market Cap $349M
  • Description
  • Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...
More about DSGN
Track This Portfolio

Track Hsbc Holdings PLC Portfolio

Follow Hsbc Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.